Higher-than-normal levels of mu-opioid receptor 1 (MOR1) in the striatum — a brain region particularly affected in Huntington’s disease — may contribute to both early psychiatric symptoms and late motor difficulties seen in Huntington’s patients, according to a study in a mouse model of the disease. The data also highlighted that MOR1 dysregulation may be one of the first markers of this neurodegenerative disease, which may help identify new potential therapeutic targets and approaches. The…

You must be logged in to read/download the full post.